ArticleNeurology and therapy2021

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.

Samuel F Hunter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.